Last Updated : December 14, 2018
Details
FilesGeneric Name:
Nivolumab
Project Status:
Complete
Therapeutic Area:
Metastatic Hepatocellular Carcinoma (HCC)
Manufacturer:
Bristol-Myers Squibb Canada
Brand Name:
Opdivo
Project Line:
Reimbursement Review
Project Number:
PC0134-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
10 mg/mL
Tumour Type:
Gastrointestinal
Indications:
Hepatocellular Carcinoma (HCC)
Funding Request:
For the treatment of adult patients with advanced (not amenable to curative therapy or local therapeutic measures) or metastatic hepatocellular carcinoma who are intolerant to or have progressed on sorafenib therapy
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : December 14, 2018